Overview

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
Alkermes, Inc.
Treatments:
Antipsychotic Agents
Aripiprazole
Aripiprazole lauroxil